Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of “Buy” by Brokerages

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $14.3333.

Several research firms have recently weighed in on EPRX. Leede Financial upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Cantor Fitzgerald boosted their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, January 15th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Friday, January 9th. Finally, Wall Street Zen raised Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th.

Eupraxia Pharmaceuticals Price Performance

Shares of EPRX stock opened at $8.35 on Monday. The stock has a market capitalization of $300.27 million, a PE ratio of -9.60 and a beta of 1.20. The business’s 50 day simple moving average is $7.57 and its 200 day simple moving average is $6.35. Eupraxia Pharmaceuticals has a one year low of $2.68 and a one year high of $9.32.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Alyeska Investment Group L.P. bought a new stake in Eupraxia Pharmaceuticals in the third quarter valued at $1,475,000. Vivo Capital LLC bought a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $7,965,000. Velan Capital Investment Management LP acquired a new position in Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $2,077,000. Integrated Wealth Concepts LLC bought a new position in Eupraxia Pharmaceuticals in the third quarter worth approximately $71,000. Finally, Bank of America Corp DE boosted its holdings in Eupraxia Pharmaceuticals by 262.9% in the third quarter. Bank of America Corp DE now owns 45,577 shares of the company’s stock worth $269,000 after acquiring an additional 33,018 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.